10-Q: Biogen Q3 2025 Earnings: Revenue Up, R&D Costs Down

Biogen Inc. reported a 2.8% increase in total revenue for Q3 2025, driven by strong performance in rare disease products and LEQEMBI, while reducing R&D expenses.

Summary

• Total revenue increased by $68.9 million (2.8%) to $2,534.7 million for Q3 2025 compared to Q3 2024.
• Diluted earnings per share increased by $0.51 (19.2%) to $3.17 for Q3 2025 compared to $2.66 in Q3 2024.
• Product revenue, net, increased by $77.5 million (4.4%) to $1,846.9 million for Q3 2025.
• Multiple Sclerosis (MS) product revenue increased by 0.7% to $1,061.5 million, primarily due to U.S. VUMERITY demand and favorable pricing, partially offset by global TECFIDERA decline.
• Rare disease product revenue increased by 7.8% to $533.3 million, driven by new product launches including SKYCLARYS ($132.9 million) and QALSODY ($26.4 million).
• ZURZUVAE revenue was $55.3 million in Q3 2025, driven by continued U.S. launch.
• Total cost and expense decreased by $37.4 million (1.9%) to $1,977.4 million for Q3 2025.
• Research and development (R&D) expense decreased by $80.1 million (15.5%) to $436.1 million for Q3 2025, due to cost reduction measures and portfolio prioritization, partially offset by higher clinical trial spend on litifilimab and felzartamab.
• Selling, general and administrative (SG&A) expense increased by $6.4 million (1.1%) to $594.8 million, due to increased sales and marketing for LEQEMBI and SKYCLARYS launches.
• Cash, cash equivalents, and marketable securities totaled approximately $4.0 billion as of September 30, 2025, up from $2.4 billion at December 31, 2024.
• Net cash flow from operations for the nine months ended September 30, 2025, was $1.7 billion, down from $2.1 billion in the prior year, primarily due to higher tax payments.
• Issued $1.75 billion in 2025 Senior Notes in May 2025 and used proceeds to redeem $1.75 billion of 4.050% Senior Notes due September 15, 2025, in June 2025.
• Acquired Alcyone Therapeutics, Inc. for an upfront cash payment of $85.0 million (expected Q4 2025 close).
• Entered strategic research arrangement with City Therapeutics, including a $16.0 million upfront payment and a $30.0 million convertible note investment.
• Entered collaboration with Stoke Therapeutics, including a $165.0 million upfront payment.
• Received $150.0 million in R&D funding from Royalty Pharma for the litifilimab program for the nine months ended September 30, 2025.
• LEQEMBI subcutaneous autoinjector (IQLIK) approved by FDA in August 2025.
• LEQEMBI monthly IV maintenance dosing approved by FDA in January 2025 and China in September 2025.
• ZURZUVAE approved in E.U. for Postpartum Depression (PPD) in September 2025 and U.K. in August 2025.
• Salanersen Phase 1b study showed positive topline results for Spinal Muscular Atrophy (SMA).
• Initiated Phase 3 PREVAIL study for felzartamab in Immunoglobulin A Nephropathy (IgAN) and PROMINENT study for felzartamab in Primary Membranous Nephropathy (PMN) in June 2025.
• Initiated Phase 3 TRANSCEND study for felzartamab in Antibody-Mediated Rejection (AMR) in March 2025.
• FDA issued a Complete Response Letter (CRL) for higher dose nusinersen (SPINRAZA), requesting Chemistry Manufacturing and Controls (CMC) module updates.
• SKYCLARYS approved in U.K. and Brazil in April 2025, and Health Canada in March 2025.
• QALSODY approved in U.K. in July 2025 and Health Canada in March 2025 (conditional).
• FDA granted Fast Track designation to BIIB080 for Alzheimer's disease in April 2025.
• Sold U.S. regulatory and commercial rights for TOFIDENCE to Organon for $51.0 million in March 2025.
• Entered new corporate headquarters lease in Cambridge, MA, for 580,000 sq ft, commencing May 31, 2028.
• European General Court annulled May 2023 EC decision granting TECFIDERA an additional year of regulatory marketing protection.
• Settled VUMERITY patent infringement proceedings with Zydus in July 2025.
• Ordered to pay Genentech $88.3 million plus interest for TYSABRI royalties in September 2025.
• Closed SEC and DOJ/SEC investigations related to ADUHELM and foreign business operations in April/May 2025.
• Received Civil Investigative Demand from Louisiana DOJ regarding 340B drug purchase policies in September 2025.
• Sold remaining commercial rights to BYOOVIZ and OPUVIZ in Europe to Samsung Bioepis in October 2025.

Sentiment

Score: 6

Explanation: The company shows revenue growth and improved EPS for the quarter, driven by new product launches and cost-saving initiatives. However, this is tempered by declining legacy product sales due to competition, a decrease in operating cash flow for the nine-month period, and ongoing litigation and regulatory challenges. Strategic acquisitions and pipeline advancements are positive, but the overall financial impact of healthcare reforms remains uncertain.

Positives

• Total revenue increased by 2.8% in Q3 2025 to $2,534.7 million and by 5.4% for the nine months ended September 30, 2025, to $7,611.2 million.
• Diluted earnings per share increased by 19.2% in Q3 2025 to $3.17.
• Rare disease product revenue grew by 7.8% in Q3 2025 and 12.9% for the nine months, driven by new product launches (SKYCLARYS, QALSODY).
• LEQEMBI collaboration revenue increased significantly by 129.6% in Q3 2025 and 293.4% for the nine months, due to continued U.S. and international launch.
• ZURZUVAE revenue of $55.3 million in Q3 2025 reflects successful U.S. launch and subsequent EU/UK approvals.
• Research and development (R&D) expense decreased by 15.5% in Q3 2025 and 13.5% for the nine months, due to cost reduction measures and portfolio prioritization.
• Strong cash position with approximately $4.0 billion in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Successful issuance of $1.75 billion in 2025 Senior Notes and redemption of existing debt, demonstrating active capital management.
• Multiple product approvals and advancements: LEQEMBI (subcutaneous, monthly IV), ZURZUVAE (EU, UK), SKYCLARYS (UK, Brazil, Canada), QALSODY (UK, Canada), BIIB080 (Fast Track designation).
• Positive topline results from Salanersen Phase 1b study for SMA, indicating potential for further development.
• Closure of SEC and DOJ/SEC investigations related to ADUHELM and foreign business operations, reducing regulatory overhang.
• Royalty Pharma funding of $150.0 million for the litifilimab program, offsetting R&D costs.

Negatives

• Global TECFIDERA revenue decreased by 27.7% in Q3 2025 and 23.2% for the nine months due to generic competition.
• Global TYSABRI revenue decreased by 2.4% for the nine months due to increased competition, including a biosimilar entrant in Europe.
• Net cash flow from operations decreased by 20.0% for the nine months ended September 30, 2025, primarily due to higher worldwide tax payments.
• Cost of sales increased by 5.6% in Q3 2025, partly due to a $104.3 million charge related to a litigation matter.
• Biosimilar revenue decreased by 5.5% for the nine months due to lower IMRALDI sales volumes and competitive pressures in Europe.
• European General Court annulled the May 2023 EC decision granting TECFIDERA an additional year of regulatory marketing protection, potentially impacting exclusivity.
• FDA issued a Complete Response Letter (CRL) for the higher dose regimen of nusinersen (SPINRAZA), requesting technical information updates, which could delay approval.
• Ordered to pay Genentech approximately $88.3 million plus interest for TYSABRI royalties, impacting profitability.
• Anticipate the IRA Medicare Part D redesign to have a modest net unfavorable impact of $50.0 million to $100.0 million on 2025 revenue, concentrated in SKYCLARYS and MS portfolio.
• Supply constraints for IMRALDI and BENEPALI biosimilars due to third-party contract manufacturer issues could adversely impact sales.

Risks

• Substantial dependence on revenue from existing products, which face increasing competition from new originator therapies, generics, prodrugs, and biosimilars.
• Risks associated with new product launches (LEQEMBI, SKYCLARYS), including obtaining and maintaining adequate reimbursement, market acceptance, and competition.
• Long-term success depends on successful development of new products and additional indications, which is expensive, uncertain, and has a high failure rate.
• Intense competition in the biopharmaceutical industry from companies with greater resources and product pipelines.
• Adverse effects if strategic and growth initiatives (acquisitions, collaborations, Fit for Growth program) are not successfully executed or anticipated benefits are not realized.
• Dependence on collaborators and third parties for revenue, development, regulatory approval, commercialization, and marketing, which are outside of full control.
• Adverse effects from current and potential future healthcare reforms (PPACA, IRA, OBBBA), including drug pricing controls, Medicare Part D redesign, and potential Most-Favored-Nation (MFN) drug pricing policies.
• Risks inherent in biosimilar commercialization, including reliance on third parties, competitive challenges, regulatory hurdles, supply chain issues, intellectual property disputes, and market acceptance.
• Inability to obtain and maintain adequate protection for data, intellectual property, and other proprietary rights, leading to potential loss of patent protection, inability to engage in certain activities, or payment of significant damages/royalties.
• Clinical trials are lengthy, complex, and expensive; failure to manage clinical activities could delay or deny regulatory approvals.
• Adverse safety events or restrictions on use/safety warnings for products can negatively affect business, sales, and stock price.
• Breakdown or breach of information systems (including cloud technologies) could lead to liability, business interruption, data breaches, and reputational harm.
• Increasing use of AI-based software presents risks such as flawed algorithms, biased data, cybersecurity risks, and potential legal liability.
• Manufacturing issues (reliance on third parties, single-source providers, global bulk supply risks, cGMP compliance, product loss) could increase costs, limit supply, and reduce revenue.
• Management, personnel, and organizational changes may disrupt operations and make it difficult to retain or attract qualified personnel.
• Failure to comply with extensive legal and regulatory requirements in the healthcare industry could lead to increased costs, penalties, and loss of business.
• Risks of doing business internationally, including geopolitical tensions (Russia-Ukraine, Middle East), tariffs, supply chain disruptions, foreign currency fluctuations, and diverse data privacy requirements.
• Incurrence of significant investment in manufacturing facilities (Solothurn, RTP) with no assurance of recoupment or full utilization.
• Illegal distribution and sale of counterfeit or unfit products or stolen products could harm reputation and business.
• Increasing use of social media platforms presents risks of noncompliance with regulations, adverse event reporting failures, and reputational damage from negative or inaccurate posts.
• Operating results are subject to significant fluctuations due to timing of charges, foreign currency exchange rates, and other factors.
• Investments in properties may not be fully realized, leading to impairment charges or significant costs if properties are vacated.
• Inability to access the capital and credit markets on favorable terms could increase financing costs.
• Indebtedness and significant contingent liabilities could adversely affect the business and limit flexibility.
• Investment portfolio is subject to market, interest, and credit risk that may reduce its value.
• No assurance of share repurchases at favorable prices, which may negatively affect stock price.
• Collaboration agreements contain change in control provisions that may discourage acquisitions.
• Effective tax rate fluctuates, and potential tax obligations may exceed accrued amounts due to changes in tax laws (e.g., OECD GloBE Model Rules).
• Environmental and operational risks, which include the cost of compliance and the risk of contamination or injury.

Future Outlook

Expect total MS revenue to continue to decline in 2025 due to increasing competition, particularly accelerating generic competition for TECFIDERA in certain EU markets and a TYSABRI biosimilar entrant in international markets. Global SPINRAZA revenue growth is anticipated to be relatively flat in 2025. Growth in rare disease revenue is expected in 2025 with continued launches of SKYCLARYS in the U.S., Europe, and other markets. Contract manufacturing revenue for full-year 2025 is anticipated to remain relatively flat compared to 2024 due to planned plant maintenance activities in Q4 2025. Core R&D expense is expected to decrease in 2025 due to portfolio prioritization, the Fit for Growth program, and Royalty Pharma funding. A slight increase in full-year 2025 SG&A expense is expected due to continued spend on LEQEMBI and SKYCLARYS product launches. The IRA's drug pricing controls and Medicare Part D redesign are anticipated to have a modest net unfavorable impact of $50.0 million to $100.0 million on 2025 revenue, concentrated in SKYCLARYS and MS portfolio products.

Management Comments

• Our long-term competitive position depends upon our success in discovering and developing innovative, cost-effective products that serve unmet medical needs, along with our ability to manufacture products efficiently and to launch and market them effectively in a highly competitive environment.
• Our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future.
• We believe that generic and biosimilar competition for many of our key products, the continued overall decline of our MS business and our investments in the launch of key new products and the development of our pipeline will have a significant adverse impact on our future cash flow from operations.
• We intend to continue committing significant resources to targeted research and development opportunities while continuing to invest in our pipeline, such as our acquisition of HI-Bio in July 2024, where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.
• We have announced a plan to resubmit the application promptly based upon readily available information regarding the SPINRAZA CRL.

Industry Context

The biopharmaceutical industry remains intensely competitive, with increasing pressure from new originator therapies, generics, prodrugs, and biosimilars, leading to significant pricing and volume reductions for branded products. Global healthcare cost-containment measures, including the U.S. Inflation Reduction Act (IRA) and potential Most-Favored-Nation (MFN) drug pricing policies, continue to exert downward pressure on drug prices and reimbursement. Geopolitical tensions and global supply chain disruptions also pose ongoing challenges. Biogen's strategic focus on neurology, specialized immunology, and rare diseases, coupled with pipeline advancements and cost-saving initiatives, positions it within a dynamic market seeking innovative solutions for complex diseases amidst evolving regulatory and economic landscapes.

Comparison to Industry Standards

• The filing highlights increased competition from generic entrants for TECFIDERA in the U.S. and international markets, and a biosimilar entrant for TYSABRI in Europe, indicating a trend of market erosion for established branded drugs, a common challenge across the pharmaceutical industry.
• The approval of LEQEMBI subcutaneous autoinjector (IQLIK) and monthly IV maintenance dosing, along with ZURZUVAE's EU and UK approvals, demonstrates Biogen's continued efforts to bring new therapies to market, aligning with the industry's focus on innovation and expanding treatment options.
• The FDA's Complete Response Letter (CRL) for a higher dose SPINRAZA regimen, requesting CMC module updates, reflects the stringent regulatory environment common across the biopharmaceutical sector, where even minor technical deficiencies can delay approvals.
• The acquisition of HI-Bio and Alcyone Therapeutics, and collaborations with City Therapeutics and Stoke Therapeutics, are consistent with industry trends of strategic partnerships and M&A to augment pipelines and leverage specialized technologies (e.g., ASO, RNAi, precision CNS delivery).
• The $104.3 million charge related to a litigation matter and the $88.3 million damages for TYSABRI royalties to Genentech underscore the significant legal and intellectual property risks prevalent in the highly litigious pharmaceutical industry.

Legal Proceedings

• Securities Litigation: Defendants in three pending securities actions in District Court related to ADUHELM, LEQEMBI, TECFIDERA, and VUMERITY, alleging federal securities law violations and seeking monetary relief.
• Derivative Actions: Named as defendants in five derivative actions in District Court related to ADUHELM, LEQEMBI, compliance controls, and 2023 earnings guidance, alleging breach of fiduciary duty, waste of corporate assets, and other claims. All derivative actions are stayed.
• IMRALDI Patent Litigation: Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS alleging infringement of EP '488 Patent by a formulation of IMRALDI. Higher Regional Court of Düsseldorf held a formulation of IMRALDI infringed German counterpart of EP '488 Patent, enjoining infringement and declaring Fresenius Kabi's right to seek damages (approximately $13.45 million plus interest and costs). Biogen has requested review of the decision.
• Litigation with Former Convergence Shareholders: Shareholder Representative Services LLC and former Convergence shareholders filed a suit seeking $49.9 million plus interest and costs for alleged breaches of contract. A final decision is pending.
• Humana Patient Assistance Litigation: Humana filed suit alleging damages related to providing MS patients with free medications and charitable contributions to non-profit organizations, alleging breach of contract, fraud, and other state law claims.
• Genentech Litigation: Court ordered Biogen liable to pay Genentech approximately $88.3 million plus interest (approximately $35.9 million as of Sep 30, 2025) for royalties on TYSABRI sales after patent expiration. Final judgment has not yet entered.
• Antitrust Litigation: Sued by multiple plaintiffs in U.S. District Court for the Northern District of Illinois alleging violations of federal antitrust laws and state laws based on contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek class action status, monetary, declaratory, and equitable relief. Walgreen Co. and The Kroger Co. filed a separate antitrust complaint.
• Neurimmune Litigation: Filed suit against Neurimmune seeking declaratory judgment and permanent injunctive relief regarding rights under a terminated collaboration agreement related to aducanumab. Neurimmune asserted counterclaims for declaratory judgment, breach of contract, and unfair competition.
• TECFIDERA E.U. Litigation: Sued Neuraxpharm, Polpharma, Sandoz, Mylan in Netherlands for damages alleging violation of regulatory marketing protection by generic TECFIDERA sales. Obtained injunction against Sandoz in Netherlands (stayed). Sued Sandoz A/S in Danish Maritime and Commercial High Court for damages, alleging violation of regulatory marketing protection (stayed).
• Government Investigations: SEC Division of Enforcement and DOJ/SEC closed matters related to ADUHELM, equity plans, and foreign business operations. Italian Competition Authority is investigating Biogen and other companies regarding BYOOVIZ. Received Civil Investigative Demand from Louisiana Department of Justice for information regarding 340B drug purchase policies.
• TYSABRI Biosimilar Patent Matter: Filed action against Sandoz Inc. and Polpharma Biologics S.A. seeking declaratory judgment of patent infringement. No trial date set.

Related Party Transactions

• Collaboration with Genentech (Roche Group) for RITUXAN, GAZYVA, LUNSUMIO, OCREVUS, and COLUMVI, involving tiered royalties and profit-sharing arrangements.
• Collaboration with Ionis Pharmaceuticals, Inc. for SMA therapies, including potential development, regulatory, and performance-based milestone payments and tiered royalties for salanersen.
• Collaboration with Eisai Co., Ltd. for LEQEMBI, involving equal sharing of product revenue, cost of sales, and development/sales & marketing expenses, and a supply agreement.
• Collaboration with UCB for dapirolizumab pegol, involving equal sharing of development, sales & marketing expenses, and profits/losses for agreed indications.
• Collaboration with Supernus Pharmaceuticals, Inc. (previously Sage Therapeutics, Inc.) for ZURZUVAE, involving equal responsibility and costs for U.S. development and commercialization, and potential tiered royalties outside the U.S.
• Collaboration with Denali Therapeutics Inc. for BIIB122, involving shared responsibility and costs for global development and profit/loss sharing for commercialization in the U.S. and China, with potential tiered royalties elsewhere.
• Collaboration with Stoke Therapeutics, Inc. for zorevunersen, involving an upfront payment of $165.0 million, shared external clinical development costs (Stoke 70%, Biogen 30%), potential development and commercial milestone payments, and tiered royalties.
• Funding agreement with Royalty Pharma for the litifilimab program, providing up to $250.0 million in co-funding and potential approval-based fixed milestone payments and mid-single digit royalties.
• In-license commitments acquired from HI-Bio with MorphoSys AG, including tiered royalties and potential development, regulatory, and commercial milestone payments (e.g., $35.0 million and $30.0 million milestones paid in April and July 2025, respectively).
• Strategic research arrangement with City Therapeutics, Inc., involving a $16.0 million upfront payment, a $30.0 million convertible note investment, and potential research, development, and sales-based milestone payments and tiered royalties.
• License arrangements with Samsung Bioepis Co., Ltd. for biosimilar products (BENEPALI, IMRALDI, FLIXABI, BYOOVIZ, OPUVIZ), involving supply at a pre-specified gross margin, potential sales-based milestones, 50% profit/loss sharing for certain agreements, and single-digit royalties.

Stakeholder Impact

• Shareholders: Potential for increased value from new product launches and pipeline advancements, but also face risks from declining legacy product sales, litigation costs, and the impact of healthcare reforms on revenue and profitability. Share repurchase program provides potential for capital return.
• Patients: Benefit from new and advanced therapies for serious diseases like Alzheimer's, SMA, FA, ALS, and PPD. However, potential delays in drug approvals (e.g., SPINRAZA CRL) or pricing/reimbursement challenges could affect access.
• Employees: Impacted by the 'Fit for Growth' cost-saving program, which includes headcount reductions (approximately 1,400 employees). Acquisitions (HI-Bio, Alcyone) may lead to integration challenges and potential talent retention issues.
• Customers (Healthcare Providers, Payors): Affected by drug pricing and reimbursement policies, including the IRA's impact on Medicare Part D and potential MFN drug pricing. Increased competition from generics/biosimilars offers lower-cost alternatives.
• Suppliers/Contract Manufacturers: Reliance on third-party suppliers and manufacturers for various aspects of the manufacturing process, including single-source providers, introduces supply chain risks. Changes in relationships (e.g., acquisition of a biosimilar contract manufacturer) could impact supply continuity.
• Creditors: The issuance of $1.75 billion in new senior notes and the redemption of existing debt demonstrate active debt management, impacting the company's leverage and interest obligations.

Next Steps

• Close the proposed acquisition of Alcyone Therapeutics, Inc. during Q4 2025.
• Oversee end-to-end development, manufacturing, and commercialization of ThecaFlex DRx.
• Make a convertible debt investment of up to $5.0 million in Neela Therapeutics, Inc.
• Resubmit the supplemental NDA for a higher dose regimen of nusinersen (SPINRAZA) promptly based on readily available information.
• Continue to launch SKYCLARYS in the U.S., Europe, and certain rest of world markets.
• Continue to launch QALSODY in international markets.
• Monitor the impact of the IRA's drug pricing controls and Medicare Part D redesign on full-year 2025 sales.
• Address supply constraints for IMRALDI and BENEPALI biosimilars.
• Continue to defend the validity of the EP 2 653 873 patent related to TECFIDERA in opposition proceedings in November 2025.
• Pay the $150.0 million milestone payment to former HI-Bio shareholders for felzartamab IgAN Phase 3 trial in Q4 2025.
• Make an upfront payment of $70.0 million to Vanqua Bio, Inc. during Q4 2025.
• Recognize a minimal gain from the sale of BYOOVIZ and OPUVIZ rights in Europe during Q4 2025.
• Samsung Bioepis will assume full responsibility for commercialization of BYOOVIZ in Europe effective January 2026.
• Continue to evaluate the potential impact of new accounting standards (ASU No. 2023-09, ASU No. 2024-03).
• Monitor the evolving global tariff landscape.
• Monitor the ongoing conflict between Russia and Ukraine and the military conflict in the Middle East for potential impacts.
• Assess the overall impact of the OBBBA on business, results of operations, and financial condition as additional guidance becomes available.
• Conduct annual goodwill impairment review as of October 31.

Key Dates

Recommendation

Biogen presents a mixed financial picture. While Q3 2025 showed revenue growth and improved EPS, driven by promising new product launches like LEQEMBI, SKYCLARYS, and ZURZUVAE, the company continues to face significant headwinds from declining legacy MS product sales due to generic and biosimilar competition. The decrease in nine-month operating cash flow and substantial litigation costs are concerns. Strategic acquisitions and pipeline advancements are positive long-term drivers, but the regulatory environment (e.g., SPINRAZA CRL, TECFIDERA patent annulment) and the uncertain impact of healthcare reforms (IRA) introduce considerable risk. The company is actively managing its debt and pursuing cost-saving initiatives, but the transition from older blockbusters to new growth drivers is ongoing and not without challenges. A 'hold' recommendation reflects the balance between the potential upside from new therapies and pipeline, and the downside risks from competitive pressures, regulatory hurdles, and operational costs. Investors should monitor the commercial ramp-up of new products, resolution of legal matters, and the effectiveness of cost-saving measures.

Keywords

Biopharmaceutical, Neurology, Rare Diseases, Immunology, Alzheimer's Disease, Multiple Sclerosis, Spinal Muscular Atrophy (SMA), Friedreich Ataxia (FA), Amyotrophic Lateral Sclerosis (ALS), LEQEMBI, SKYCLARYS, SPINRAZA, QALSODY, ZURZUVAE, Biosimilars, SEC Filing, Financial Results, R&D Pipeline, Acquisitions, Collaborations, Drug Pricing, IRA, Corporate Strategy